Tekmira Pharmaceuticals Corporation Provides Corporate Update on RNAi Therapeutics Pipeline
Published: Oct 09, 2013
VANCOUVER, British Columbia, Oct. 8, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced the key programs and goals into 2014 for its RNAi therapeutic product pipeline.
Help employers find you! Check out all the jobs and post your resume.